Takeda, Others Look To Overseas Growth To Offset Sluggish Japan Market
This article was originally published in PharmAsia News
Takeda Pharmaceutical and fellow Japanese drug makers share a need to look abroad for ways to increase business in a shrinking domestic market. That need was behind Takeda's largest-ever acquisition bid by a Japanese drug maker for a foreign firm, the $8.8 billion offer for the U.S. biotech Millennium Pharmaceuticals. Takeda has a weak business structure in the U.S. and Europe when compared with foreign competitors and needed an acquisition. The domestic pharmaceutical market is considered sluggish despite 4.6 percent growth last year. (Click here for more - a subscription may be required
You may also be interested in...
TOKYO - The pharmaceutical market is rapidly increasing in complexity and pharmaceutical companies need to strengthen their 'mekiki ryoku' - translated 'eye for good judgment' in Japanese - said Ryoichi Inoue of Pharma Marketing Consultant, who is a former marketing executive at Roche in Japan
Two new projects have begun, one on standardizing the assessment of immune responses in individuals vaccinated in clinical trials, the other to improve understanding of potential immunity in patients who have been infected with SARS-CoV-2.
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.